CHMP Rejects EU Marketing Application for Arimoclomol, EC Decision Due Within 67 Days
ZVRA sits 26% above its 52-week low of $8.01.
Summary
The EMA's CHMP adopted a negative opinion on Zevra's EU marketing application for arimoclomol in Niemann-Pick disease type C, a material setback to the company's planned European expansion. The European Commission now has 67 days to issue its final decision, which will determine whether the application can proceed to authorization. Zevra will keep its expanded access program running for eligible patients, but that provides no commercial EU authorization. The company's Q3 2026 filing already flagged the European arimoclomol application as in re-examination, so this confirms the review has gone against Zevra at the committee stage. The U.S. business is carrying the story financially — Q3 revenue of $37.8 million, up 45%, with $270.9 million in cash and no debt — so the hit is to the EU growth option rather than near-term liquidity. Watch the European Commission's final ruling within 67 days.
At the time of this announcement, ZVRA was trading at $10.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $664.1M. The 52-week trading range was $8.01 to $15.04. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.